16.05.2022 - Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a substantial, at least 10-fold reduction in MRD following . Seite 1
JANUARY - MARCH IN SUMMARY Net sales for the period amounted to KSEK 1,794 (-).Result for the period amounted to KSEK -27,582 (-41,571).Earnings and diluted earnings per share totaled SEK -0.14 (-0.25).Immunicum
Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, announced the appointment of Leopold Bertea
COMBINATION OF CANCER RELAPSE VACCINE CANDIDATE WITH 5'-AZACITIDINE AND VENETOCLAX SHOWS SUPERIOR TUMOR REDUCTION IN AN AML MODEL Immunicum AB ("Immunicum" publ; IMMU.ST), a biopharmaceutical
Immunicum AB , a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming. | April 19, 2022